CTI BioPharma Corp. (CTIC)
9.10
0.01 (0.11%)
At close: Jun 23, 2023, 7:58 PM
0.11% (1D)
| Bid | n/a |
| Market Cap | 1.2B |
| Revenue (ttm) | 75.77M |
| Net Income (ttm) | -77.01M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -16.84259259259259 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 5,558,437 |
| Avg. Volume (20D) | 5,661,603 |
| Open | 9.10 |
| Previous Close | 9.09 |
| Day's Range | 9.09 - 9.10 |
| 52-Week Range | 4.01 - 9.10 |
| Beta | 0.83 |
About CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.;...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 1997
Employees 127
Stock Exchange NASDAQ
Ticker Symbol CTIC
Website https://www.ctibiopharma.com